 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...194195196197198199200201202203204...235236» |
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 12, 2017
P2, N=25, Completed, Sponsor: Wake Forest University Health Sciences
No longer recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment closed: APPROACH: Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets (clinicaltrials.gov) - Jan 11, 2017
P2, N=218, Active, not recruiting, Sponsor: Yonsei University
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- || Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jan 11, 2017
P1, N=60, Recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> May 2017
- MM-151 / Merrimack
Enrollment change, Trial withdrawal, Metastases: Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 11, 2017
P1/2, N=0, Withdrawn, Sponsor: Merrimack Pharmaceuticals
Trial primary completion date: Dec 2016 --> May 2017 N=28 --> 0 | Recruiting --> Withdrawn
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - Jan 10, 2017
P1, N=45, Active, not recruiting, Sponsor: University of Chicago
N=28 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Dec 2016 --> Apr 2017
- || oxaliplatin / Generic mfg., capecitabine / Generic mfg.
New P3 trial, Combination therapy, Metastases: IV Ascorbic Acid in Advanced Gastric Cancer (clinicaltrials.gov) - Jan 10, 2017
P3, N=200, Not yet recruiting, Sponsor: Sun Yat-sen University
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment change, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 6, 2017
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Apr 2017 N=89 --> 52
- |||||||||| Imkeldi (imatinib) / Shorla Oncology
IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 4, 2017
P3, N=700, Not yet recruiting, Sponsor: Children's Oncology Group
- |||||| pegilodecakin (LY3500518) / Eli Lilly
Enrollment open, Trial primary completion date, Combination therapy, Metastases: Sequoia: Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 4, 2017
P3, N=566, Recruiting, Sponsor: ARMO BioSciences
N=89 --> 52 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Jan 2019
- ||||| IMM-101 / Immodulon
New P1/2 trial: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) - Jan 3, 2017
P1/2, N=300, Not yet recruiting, Sponsor: Immodulon Therapeutics Ltd
- Trial initiation date: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 3, 2017
P2, N=35, Recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Jan 2019 Initiation date: Dec 2016 --> Jun 2015
- ||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial initiation date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 3, 2017
P2, N=56, Not yet recruiting, Sponsor: Children's Oncology Group
Initiation date: Dec 2016 --> Jun 2015 Initiation date: Sep 2017 --> Jan 2017
- Enrollment open, Trial primary completion date: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 3, 2017
P2, N=35, Recruiting, Sponsor: Sun Yat-sen University
Initiation date: Sep 2017 --> Jan 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Feb 2018
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
New P3 trial: GASTFOX: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA (clinicaltrials.gov) - Dec 30, 2016
P3, N=506, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 28, 2016
P1/2, N=30, Not yet recruiting, Sponsor: Taiwan Leader Biotech Corp.
Active, not recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Feb 2018 Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Metastases: ARMANI: Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (clinicaltrials.gov) - Dec 28, 2016
P3, N=280, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- Enrollment open, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Dec 28, 2016
P2, N=26, Recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting Suspended --> Recruiting
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Dec 27, 2016
P3, N=1266, Recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Recruiting N=870 --> 1266
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Trial initiation date: OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (clinicaltrials.gov) - Dec 27, 2016
P3, N=268, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
N=870 --> 1266 Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016
- New P2 trial, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Dec 27, 2016
P2, N=20, Not yet recruiting, Sponsor: OncoSil Medical Limited
- || Alymsys (bevacizumab-maly) - Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi / Iko, Stada
Enrollment closed: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN (clinicaltrials.gov) - Dec 23, 2016
P1, N=142, Active, not recruiting, Sponsor: mAbxience S.A
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016 Completed --> Active, not recruiting
- |||| Enrollment open, Metastases: POLAF: Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms (clinicaltrials.gov) - Dec 21, 2016
P2, N=100, Recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- | NN1213 / Novo Nordisk
Trial completion, Surgery: Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas (clinicaltrials.gov) - Dec 21, 2016
P3, N=100, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- leucovorin calcium / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant (clinicaltrials.gov) - Dec 20, 2016
P2, N=46, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Feb 2018
- ||| veliparib (ABT-888) / AbbVie
Enrollment change, Combination therapy, Metastases: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 20, 2016
P1/2, N=79, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Feb 2017 --> Feb 2018 N=48 --> 79
- || New P3 trial, Monotherapy, Mismatch repair, PD(L)-1 Biomarker, IO biomarker: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (clinicaltrials.gov) - Dec 20, 2016
P3, N=439, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Trial primary completion date: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients (clinicaltrials.gov) - Dec 19, 2016
P2, N=31, Recruiting, Sponsor: University of Michigan Cancer Center
N=48 --> 79 Trial primary completion date: Feb 2017 --> Feb 2018
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Dec 19, 2016
P1, N=32, Recruiting, Sponsor: Oncolytics Biotech
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Dec 2016 --> Apr 2017
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Dec 19, 2016
P1, N=60, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2016 --> Apr 2017 Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 14, 2016
P2, N=47, Recruiting, Sponsor: Centre Jean Perrin
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Jul 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 14, 2016
P3, N=380, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Sep 2014 --> Oct 2015
- Trial primary completion date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Dec 13, 2016
P=N/A, N=42, Active, not recruiting, Sponsor: Philip Philip
Trial primary completion date: Sep 2014 --> Oct 2015 Trial primary completion date: Sep 2016 --> Dec 2016
- || Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Dec 13, 2016
P2, N=245, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Dec 2012 --> Apr 2011
- |||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: CALGB: Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 13, 2016
P3, N=2334, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Dec 2012 --> Apr 2011 Trial primary completion date: Mar 2013 --> Feb 2015
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Dec 9, 2016
P1, N=0, Withdrawn, Sponsor: University of Chicago
Trial primary completion date: Mar 2013 --> Feb 2015 N=45 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2017 --> Aug 2016
- | New P2 trial: Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil (clinicaltrials.gov) - Dec 9, 2016
P2, N=54, Recruiting, Sponsor: Sun Yat-sen University
- |||| Tepylute (thiotepa ready to dilute) / Shorla Oncology, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date: COG-ACNS0334: Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma (clinicaltrials.gov) - Dec 8, 2016
P3, N=96, Active, not recruiting, Sponsor: Children's Oncology Group
N=45 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2017 --> Aug 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- Trial primary completion date, Metastases: Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=14, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Feb 2008 --> Apr 2005
- Trial primary completion date, Metastases: Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=19, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Feb 2008 --> Apr 2005 Trial primary completion date: Oct 2009 --> Apr 2004
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=42, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Oct 2009 --> Apr 2004 Trial primary completion date: Oct 2009 --> Jan 2005
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Dec 7, 2016
P2, N=100, Recruiting, Sponsor: Takeda
Trial primary completion date: Oct 2009 --> Jan 2005 Trial primary completion date: Sep 2016 --> Aug 2017
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Dec 7, 2016
P2, N=33, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Aug 2017 Trial primary completion date: Jun 2017 --> Jun 2018
- | Trial completion, Metastases: Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 6, 2016
P2, N=14, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed
- | Trial completion, Metastases: Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 6, 2016
P2, N=19, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer (clinicaltrials.gov) - Dec 6, 2016
P2, N=42, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open, Surgery: A021501: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Dec 5, 2016
P2, N=134, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2 trial: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 4, 2016
P2, N=35, Active, not recruiting, Sponsor: Sun Yat-sen University
- ||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P2 trial: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 4, 2016
P2, N=56, Not yet recruiting, Sponsor: Children's Oncology Group
- | Vectibix (panitumumab) / Amgen
New P2 trial: PANIRINOX: Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Dec 2, 2016
P2, N=209, Not yet recruiting, Sponsor: UNICANCER
- || Erbitux (cetuximab) / Eli Lilly
Biomarker, New P2/3 trial, Monotherapy, Metastases: Cetuximab Monotherapy Maintenance Treatment in mCRC (clinicaltrials.gov) - Nov 30, 2016
P2/3, N=500, Not yet recruiting, Sponsor: Ruijin Hospital